• 回到顶部
  • 4006560232
  • 微信扫码咨询

BFB

 

人肺腺癌细胞NCI-H292

 

BLUEFBIO Product Sheet

 

细胞名称

人肺腺癌细NCI-H292                  

img1

货物编码

BFN608006101

产品规格

T25培养x1

1.5ml冻存x2

细胞数量

1x10^6

1x10^6

保存温度

37

-198

运输方式

常温保温运输

干冰运输

安全等级

1

用途限制

仅供科研用途 1类

 

培养体系

DMEM高糖培养基Hyclone+10%胎牛血清Gibco+1%双抗Hyclone

培养温度

37

二氧化碳浓度

5%

简介

人肺腺癌细NCI-H292细胞株源自肺支气管黏液上皮样癌的淋巴结转移灶;先用成份限定的培养基分离得到,然后换成含血清的培养基培养。培养条件下该细胞保留了黏液上皮的特性,可从其超微结构的表现和多种鳞状上皮分化标记的表达而判断。该细胞支HBV的生长,左旋多巴脱羧酶阴性。该细胞可以作为筛选模型,将人类亚基因组片段转染入细胞来研HBV及其自身基因在病毒性肝炎和肝癌发生中的作用。该细胞角蛋白、波形蛋白、黏液洋红染色阳线,但神经丝三联蛋白阴性。人肺腺癌细NCI-H292细胞株由青旗(上海)生物技术发展有限公司2019年引种ATCCCRL-1848 

注释

Part of: Cancer Cell Line Encyclopedia (CCLE) project.

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Microsatellite instability: Instable (MSI-low) (Sanger).

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep RNAseq analysis.

Omics: DNA methylation analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis.

STR信息

AmelogeninXCSF1PO10D13S3171112D16S539913D18S5116D19S4331213.2D21S1128D2S13382124D3S135816D5S81813D7S82010D8S11791114FGA2226TH018TPOX811vWA16

参考文献

PubMed=3335022

Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.

Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.

Cancer Res. 48:589-601(1988)

 

PubMed=1311061

Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., Gazdar A.F.

p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Oncogene 7:171-180(1992)

 

PubMed=8806092; DOI=10.1002/jcb.240630505

Phelps R.M., Johnson B.E., Ihde D.C., Gazdar A.F., Carbone D.P., McClintock P.R., Linnoila R.I., Matthews M.J., Bunn P.A. Jr., Carney D.N., Minna J.D., Mulshine J.L.

NCI-Navy Medical Oncology Branch cell line data base.

J. Cell. Biochem. 63 Suppl. 24:32-91(1996)

 

PubMed=12539049; DOI=10.10381083

Tonon G., Modi S., Wu L., Kubo A., Coxon A.B., Komiya T., O'Neil K., Stover K., El-Naggar A., Griffin J.D., Kirsch I.R., Kaye F.J.

t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway.

Nat. Genet. 33:208-213(2003)

 

PubMed=15193437; DOI=10.1016/j.cancergencyto.2003.10.007

Tonon G., Gehlhaus K.S., Yonescu R., Kaye F.J., Kirsch I.R.

Multiple reciprocal translocations in salivary gland mucoepidermoid carcinomas.

Cancer Genet. Cytogenet. 152:15-22(2004)

 

PubMed=17332333; DOI=10.1158/0008-5472.CAN-06-3339

Okabe T., Okamoto I., Tamura K., Terashima M., Yoshida T., Satoh T., Takada M., Fukuoka M., Nakagawa K.

Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.

Cancer Res. 67:2046-2053(2007)

 

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=22460905; DOI=10.1038/nature11003

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=25485619; DOI=10.1038/nbt.3080

Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.

A comprehensive transcriptional portrait of human cancer cell lines.

Nat. Biotechnol. 33:306-312(2015)

 

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

 

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005

Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.

Characterization of human cancer cell lines by reverse-phase protein arrays.

Cancer Cell 31:225-239(2017)

 

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

 

PubMed=31068700; DOI=10.1038/s41586-019-1186-3

Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Nature 569:503-508(2019)

 

 

验收细胞注意事 

1、收到人肺腺癌细NCI-H292细胞,请查看瓶子是否有破裂,培养基是否漏出,是否浑浊,如有请尽快联系 

2、收到人肺腺癌细NCI-H292细胞,如包装完好,请在显微镜下观察细胞,由于运输过程中的问题,细胞培养瓶中的贴壁细胞有可能从瓶壁中脱落下来,显微镜下观察会出现细胞悬浮的情况,出现此状态时,请不要打开细胞培养瓶,应立即将培养瓶置于细胞培养箱里静 3-5 小时左右,让细胞先稳定下,再于显微镜下观察,此时多数细胞会重新贴附于瓶壁。如细胞仍不能贴壁,请用台盼蓝染色法鉴定细胞活力,如台盼蓝染色证实细胞活力正常请按悬浮细胞的方法处理 

3、收到人肺腺癌细NCI-H292细胞后,请镜下观察细胞,用恰当方式处理细胞。若悬浮的细胞较多,请离心收集细胞,接种到一个新的培养瓶中。弃掉原液,使用新鲜配制的培养基,使用进口胎牛血清。刚接到细胞,若细胞不多 血清浓度可以加 15%去培养。若细胞迏 80% ,血清浓度还是 10 

4、收到人肺腺癌细NCI-H292细胞时如无异常情 ,请在显微镜下观察细胞密度,如为贴壁细胞,未超80%汇合度时,将培养瓶中培养基吸出,留 5-10ML 培养基继续培养:超 80%汇合度时,请按细胞培养条件传代培养。如为悬浮细胞,吸出培养液1000 /分钟离 3 分钟,吸出上清,管底细胞用新鲜培养基悬浮细胞后移回培养瓶 

5、将培养瓶置 37培养箱中培养,盖子微微拧松。吸出的培养基可以保存在灭菌过的瓶子里,存放 4冰箱,以备不时之需 

624 小时后,人肺腺癌细NCI-H292细胞形态已恢复并贴满瓶壁,即可传代。(贴壁细胞)将培养瓶里的培养基倒去, 3-5ml(以能覆盖细胞生长面为准PBS  Hanks液洗涤后弃去。 0.5-1ml 0.25% EDTA 的胰酶消化,消化时间以具体细胞为准,一 1-3 分钟,不超 5 分钟。可以放37培养箱消化。轻轻晃动瓶壁,见细胞脱落下来,加 3-5ml 培养基终止消化。用移液管轻轻吹打瓶壁上的细胞,使之完全脱落,然后将溶液吸入离心管内离心1000rpm/5min。弃上清,视细胞数量决定分瓶数,一般一传二,如细胞量多可一传三,有些细胞不易传得过稀,有些生长较快的细胞则可以多传几瓶,以具体细胞和经验为准。(悬浮细胞)用移液管轻轻吹打瓶壁,直接将溶液吸入离心管离心即可 

7、贴壁细 ,悬浮细胞。严格无菌操作。换液时,换新的细胞培养瓶和换新鲜的培养液375%CO2 培养。

 

特别提醒 原瓶中培养基不宜继续使用,请更换新鲜培养基培养。